Psychedelics as Novel Therapeutics for Chronic Pain in Veterinary Medicine: A Hypothesis-Driven Protocol Using Low-Dose 1-Cyclopropionyl-D-lysergic Acid Diethylamide (1cp-LSD) in Canine Osteoarthritis. [PDF]
Hernández-Álvarez E +3 more
europepmc +1 more source
Psychedelic-like effects induced by 2,5-dimethoxy-4-iodoamphetamine, lysergic acid diethylamide, and psilocybin in male and female C57BL/6J mice. [PDF]
McGriff SA +5 more
europepmc +1 more source
Multimodal creativity assessments following acute and sustained microdosing of lysergic acid diethylamide. [PDF]
Murphy RJ +6 more
europepmc +1 more source
Use of Lysergic Acid Diethylamide by Major Depression Status. [PDF]
Walsh CA +4 more
europepmc +1 more source
Self-inflicted neck wounds under influence of lysergic acid diethylamide: A case report and literature review. [PDF]
Le Daré B +4 more
europepmc +1 more source
Large-scale brain connectivity changes following the administration of lysergic acid diethylamide, d-amphetamine, and 3,4-methylenedioxyamphetamine. [PDF]
Avram M +12 more
europepmc +1 more source
Perceived Risk of Trying Lysergic Acid Diethylamide in the United States from 2015 to 2019: Are Americans Assessing Lysergic Acid Diethylamide's Risk Profile More Favorably? [PDF]
Barnett BS +6 more
europepmc +1 more source
Lysergic acid diethylamide stimulates cardiac human H2 histamine and cardiac human 5-HT4-serotonin receptors. [PDF]
Gergs U +8 more
europepmc +1 more source

